Perspective Therapeutics Adds Medical Device Veteran to Board
Ticker: CATX · Form: 8-K · Filed: Aug 19, 2024 · CIK: 728387
Sentiment: neutral
Topics: board-appointment, management-change, medical-devices
TL;DR
Perspective Therapeutics just added a big-name medtech exec to their board. Expect new product moves.
AI Summary
Perspective Therapeutics, Inc. announced on August 16, 2024, the election of Dr. David W. Schramm to its Board of Directors. Dr. Schramm brings extensive experience in medical device development and commercialization, having previously served as President and CEO of Lumen, Inc. and in leadership roles at Boston Scientific Corporation.
Why It Matters
The addition of Dr. Schramm, with his proven track record in the medical device industry, could signal a strategic focus on product development and market expansion for Perspective Therapeutics.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding board composition and does not involve financial distress or significant operational changes.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Dr. David W. Schramm (person) — Newly elected Director
- Lumen, Inc. (company) — Former employer of Dr. Schramm
- Boston Scientific Corporation (company) — Former employer of Dr. Schramm
FAQ
What specific expertise does Dr. David W. Schramm bring to Perspective Therapeutics' board?
Dr. Schramm brings extensive experience in medical device development and commercialization, including his previous roles as President and CEO of Lumen, Inc. and leadership positions at Boston Scientific Corporation.
When was Dr. David W. Schramm elected to the board?
Dr. David W. Schramm was elected to the Board of Directors on August 16, 2024.
What is Perspective Therapeutics, Inc.'s primary business?
Perspective Therapeutics, Inc. is involved in the surgical and medical instruments & apparatus industry, as indicated by its SIC code 3841.
Has Perspective Therapeutics, Inc. undergone any previous name changes?
Yes, the company was formerly known as Isoray, Inc. (name change effective December 31, 2018) and IsoRay, Inc. (name change effective August 5, 2005), and prior to that, CENTURY PARK PICTURES CORP (name change effective July 3, 1992).
What is the filing date and report date for this 8-K?
This 8-K was filed as of August 19, 2024, and the earliest event reported is dated August 16, 2024.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-08-19 17:20:07
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20240816.htm (8-K) — 36KB
- 0000950170-24-098685.txt ( ) — 143KB
- catx-20240816.xsd (EX-101.SCH) — 23KB
- catx-20240816_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: August 19, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer